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Abstract
Background: Except for overall survival, whether or not waiting time for treatment could influences other domains
of cancer patients’ overall well-being is to a large extent unknown. Therefore, we performed this study to determine
the effect of waiting time for cancer treatment on the mental health of patients with esophageal or gastric cancer.
Methods: Based on the Swedish National Quality Register for Esophageal and Gastric Cancers (NREV), we followed
7,080 patients diagnosed 2006–2012 from the time of treatment decision. Waiting time for treatment was defined as
the interval between diagnosis and treatment decision, and was classified into quartiles. Mental disorders were
identified by either clinical diagnosis through hospital visit or prescription of psychiatric medications. For patients
without any mental disorder before treatment, the association between waiting time and subsequent onset of mental
disorders was assessed by hazard ratios (HRs) with 95% confidence interval (CI), derived from multivariable-adjusted
Cox model. For patients with a preexisting mental disorder, we compared the rate of psychiatric care by different
waiting times, allowing for repeated events.
Results: Among 4,120 patients without any preexisting mental disorder, lower risk of new onset mental
disorders was noted for patients with longer waiting times, i.e. 18–29 days (HR 0.86; 95% CI 0.74-1.00) and 30–60 days
(HR 0.79; 95% CI 0.67-0.93) as compared with 9–17 days. Among 2,312 patients with preexisting mental disorders,
longer waiting time was associated with more frequent psychiatric hospital care during the first year after treatment
(37.5% higher rate per quartile increase in waiting time; p for trend = 0.0002). However, no such association was
observed beyond one year nor for the prescription of psychiatric medications.
Conclusions: These data suggest that waiting time to treatment for esophageal or gastric cancer may have different
mental health consequences for patients depending on their past psychiatric vulnerabilities. Our study sheds further
light on the complexity of waiting time management, and calls for a comprehensive strategy that takes into account
different domains of patient well-being in addition to the overall survival.
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Background
Given that the impact of tumor stage on survival is undis-
puted, it is problematic that the majority of tumors are di-
agnosed at a relatively advanced stage, when accelerated
tumor growth and metastasis formation are imminent
[1, 2]. Therefore, it is logical to believe that a timely
diagnostic work-up and treatment are of critical im-
portance for the subsequent disease course and survival
of the patients. However, previous studies, either from
observational investigations [3, 4] or interventional
studies (‘Cancer waiting times targets’ project [5], intro-
duced by UK government in 2000 [6]) failed to show a
clear survival benefit of shortened waiting time for cancer
treatment. This was true even for relatively aggressive can-
cers, e.g. esophageal, gastric cancers [7, 8] and pancreatic
cancer [6]. Yet, whether or not shorter waiting time for
treatment influences other domains of cancer patients’
overall well-being is to a large extent unknown.
Cancer patients have been shown to have increased
risks of multiple mental disorders both immediately after
cancer diagnosis and later on [9, 10]. Knowledge about
determinants for such risk increase may shed light on
potential interventions. Due to the multimodality cancer
diagnostics and therapies to date, waiting time for cancer
treatment is likely to be increasing [11–13]. There is
therefore an urgent need to clarify the impact of the ex-
tended waiting time on patient well-being in general, in-
cluding the subsequent risk of mental disorders. To this
end, we performed a cohort study to address the effect
of waiting time for cancer treatment on the mental
health of patients with newly diagnosed esophageal or
gastric cancer.
Methods
Database and study design
Our study was based on the National Registry for
Esophageal and Gastric Cancers (NREV), which included
all patients with a diagnosis of esophageal or gastric can-
cer in Sweden. Details about this register, including its
validity, have been described elsewhere [14]. Briefly, the
register was officially launched in 2006, where patients
were recruited from all health care providers diagnosing
and managing gastric and esophageal cancers in Sweden.
With regular checking with the Swedish Cancer Register
to identify any potential additional patients, the NREV
database has an average coverage of 92% for each calendar
year [14]. Comprehensive information regarding diagnosis
and treatment (mainly operations) was collected through
questionnaires completed by the responsible physicians.
The register was further cross-linked to the nationwide
Cause of Death Register, Patient Register, Prescribed Drug
register, and Emigration Register, obtaining information
on follow-up outcomes of these patients.
In total, 7,984 patients with either an esophageal or
gastric cancer were registered in NREV during 2006–
2012. We excluded patients with conflict information
(died or emigrated before diagnosis, n = 60), or with
missing (567) or incorrect (275) information on the date
of treatment decision, leaving 7,080 patients (88.7%) in
the present analyses. All patients were followed until
death, emigration out of Sweden, or December 31, 2012,
whichever occurred first. This study was approved by
the Regional Ethical Review Board in Stockholm, Sweden
(Dnr 2013/596-31/3). Since we used de-identified register
data, individual informed consent was not sought in line
with institutional regulations.
Waiting time for cancer treatment
Since the exact starting date of cancer treatment was
not available for patients without surgical treatment in
NREV, we used the date of treatment decision as a proxy
of treatment initiation for all participants. Waiting time
for cancer treatment was accordingly defined as the time
interval between cancer diagnosis and treatment decision.
For most of the patients, treatment started several days
after treatment decision. For patients that received pri-
mary surgical treatment (22%), however, the actual waiting
time until surgery might be postponed because of sub-
optimal physical status, routine pre-operation exams, or
simply a queue to surgery. Nevertheless, a strong cor-
relation was detected between the waiting time from
cancer diagnosis to surgery and the waiting time between
diagnosis and treatment decision (Pearson correlation
coefficient = 0.86).
Ascertainment of mental disorders
We ascertained mental disorders in two ways. Through
cross-linkage to the Swedish Patient Register, we identified
all inpatient or outpatient hospital visits with a mental dis-
order as one of the discharge or outpatient diagnoses,
using the 10th Swedish revision of International Classifica-
tion of Diseases codes (ICD-10: F10-F99). To complement
the definition of mental disorders by using hospital diag-
noses alone, we additionally assessed the use of psychiatric
medications, by linking the cohort to Prescribed Drug
Register. The selected psychiatric medications included
antipsychotics (ATC code: N05A), anxiolytics (N05B) and
antidepressants (N06A). Patients with any hospital visit or
drug prescription with the above-mentioned ICD or ATC
codes before treatment decision were defined as having a
preexisting mental disorder. In sub-analyses, we specific-
ally examined depression (ICD10: F32 or F33; ATC code
N06A) and anxiety (ICD10: F40 or F41; ATC code N05B).
Statistical analyses
We first presented the basic characteristics of patients
with different waiting times for treatment. The patients
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with a waiting time greater than 60 days (n = 648, 9.2%)
were then excluded from the following analyses, since
such long delay was unusual and might allegedly reflect
additional complexity of the disease or a strong wish of
the patients. The remaining cancer patients were classi-
fied into four groups (≤8 days, 9–17 days, 18–29 days,
or 30–60 days), according to quartile distributions. Be-
cause a large proportion of patients presented with a his-
tory of mental disorder before treatment decision (35%),
we performed separately the primary analyses for pa-
tients with and without such history.
Patients without previous mental disorders
For 4,120 patients without any mental disorders before
treatment decision, we followed them from date of treat-
ment decision until first diagnosis of mental disorder
(captured by either hospital visit or prescription of psy-
chiatric drugs), emigration, death, or December 31, 2012,
whichever occurred first. The association between waiting
time and risk of mental disorder was examined by com-
paring the respective waiting time groups. We calcu-
lated hazard ratios (HRs) with their 95% confidence
intervals (CIs) by Cox model, adjusting for age at diag-
nosis, sex, marital status (single, married, divorce, or
widow/widower), education level (<9 years, 9–12 years,
or >12 years), physical status (The American Society of
Anesthesiologists (ASA) classification <2, or 2 and above),
cancer type (esophageal or gastric cancer), pathological/
clinical (if pathological stage unavailable) stage (0-II stage,
III stage, or IV stage), planned treatment type (curative,
palliative, or supportive treatment), multidisciplinary
(MDC) meeting (yes or no), admission pathway (general
physician referral or emergency visit), and hospital volume
(low, median, or high). Since a dramatically increased risk
of mental disorders around cancer diagnosis has been
reported [10], we used time since cancer diagnosis as
the underlying timescale for Cox models after taking
into account the delayed cohort entry (the number of
days between cancer diagnosis and treatment decision).
The proportional hazards assumption was checked graph-
ically by Schoenfeld’s partial residuals. Neither waiting
time groups nor the above covariates appeared to violate
this assumption. Cumulative incidence curves of mental
disorders for different waiting time groups were graphed
using the Nelson-Aalen method.
To assess potential effect modifiers of the studied as-
sociations, we performed sub-group analyses by different
characteristics (e.g. sex, age group, etc.). We then separ-
ately analyzed mental disorders identified through hos-
pital diagnosis alone and psychiatric medications alone
assuming that mental disorders identified through hos-
pital visits represent a severer phenotype compared to
mental disorders identified through prescribed medica-
tions alone. Lastly, in addition to lumping together all
mental disorders, we individually assessed HRs for de-
pression and anxiety disorders.
Patient with previous mental disorders
For 2,179 patients with a mental disorder history before
cancer diagnosis and 133 patients with a newly onset
mental disorder during the waiting time for treatment,
we compared the rate of psychiatric care (either through
hospital visit or prescription of psychiatric medication)
after treatment decision between different waiting time
groups by extended Cox models (counting process model)
[15], enabling inclusion of repeated events. Due to the
overall violated proportional hazard assumption we di-
vided the follow-up period (<1 year and ≥1 year) and
fitted separate models. The Cox models were adjusted
for all covariates stated above.
Sensitivity analysis
A sensitivity analysis was conducted among patients that
received surgical treatment alone (without preoperative
treatment, n = 1618), for whom the waiting time to the
actual treatment (surgery) could be estimated precisely.
We repeated all the above-mentioned analyses to valid-
ate the results of the main analyses.
To assess potential impact of different time scales on
the study results, we further used time since treatment
decision, as well as time since 60 days after cancer diag-
nosis, as the underlying time scales in the Cox models.
A p value less than 0.05 was considered to be statisti-
cally significant. All analyses were conducted in SAS
statistical software, version 9.4 (Cary, NC).
Results
Table 1 illustrates the baseline characteristics of all par-
ticipants, as well as by the different groups of waiting
time for treatment. Overall, the mean age at the time of
cancer diagnosis was 74 years and 65.7% of the patients
were male. Patients with shorter waiting times generally
had more advanced disease. In particular, patients with
the shortest waiting time (1–8 days) tended to be older,
with worse physical status, more advanced cancer stage
and were more likely to be admitted through emergency
visit. Most of these patients received their treatment de-
cision without an MDC meeting (60.8%). Since patients
with the shortest waiting time obviously differed from
the other patients, we used the second shortest waiting
time group (‘9-17 days’) as the reference group in all
following analyses.
Patients without previous mental disorders
Among patients without a previous history of mental dis-
order, 1,268 developed a mental disorder during follow-
up. In general, we observed a decreased risk of mental
disorder for patients with longer waiting times, compared
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Table 1 Characteristics of patients with a newly diagnosed esophageal or gastric cancer, by different waiting time groups
Characteristics All Waiting time groups
1–8 days 9–17 days 18–29 days 30–60 days >60 days
Number of patients 7080 1733 1542 1556 1601 648
Demographic factors
Age, mean ± SD, years 71.4 ± 11.9 73.7 ± 12.5 70.4 ± 12.2 70.4 ± 11.6 71.1 ± 11.1 70.3 ± 11.1
Gender (% male) 65.7 63.1 67.1 66.3 65.5 69.0
Material status, n (%)
Single 914 (12.9) 235 (13.6) 227 (14.7) 180 (11.6) 189 (11.8) 83 (12.8)
Married 3626 (51.2) 797 (46.0) 806 (52.3) 843 (54.2) 842 (52.6) 338 (52.2)
Divorce 1158 (16.4) 284 (16.4) 236 (15.3) 242 (15.6) 284 (17.7) 112 (17.3)
Widow/widower 1368 (19.3) 411 (23.7) 271 (17.6) 288 (18.5) 283 (17.7) 115 (17.8)
Missing 14 (0.2) 6 (0.3) 2 (0.1) 3 (0.2) 3 (0.2) 0 (0.0)
Education level, n (%)
< =9 years 3070 (43.4) 778 (44.9) 655 (42.5) 643 (41.3) 700 (43.7) 294 (45.4)
10–12 years 2561 (36.2) 586 (33.8) 545 (35.3) 578 (37.2) 600 (37.5) 252 (38.9)
> =12 years 1038 (14.7) 227 (13.1) 239 (15.5) 255 (16.4) 235 (14.7) 82 (12.7)
Missing 411 (5.8) 142 (8.2) 103 (6.7) 80 (5.1) 66 (4.1) 20 (3.1)
Disease-related factors
Time of follow-up (months, until death, emigration or the end of study)
Mean ± SD 15.6 ± 18.0 10.4 ± 16.1 13.0 ± 15.8 16.3 ± 17.7 18.5 ± 18.0 26.6 ± 21.5
Hospital Volume
Low (<20 cases/year) 3310 (46.8) 975 (56.3) 749 (48.6) 664 (42.7) 659 (41.2) 263 (40.5)
Median (20–40 cases/year) 1868 (26.4) 442 (25.5) 456 (29.5) 420 (27.0) 387 (24.1) 163 (25.2)
High (>40 cases/year) 1899 (26.8) 314 (18.1) 337 (21.9) 471 (30.3) 555 (34.7) 222 (34.3)
Missing 2 (0.0) 0 (0.0) 1 (0.0) 0 (0.0) 0 (0.0) 3 (0.0)
ASA physical status, n (%)
I-II 4319 (61.0) 902 (52.1) 970 (62.9) 1023 (65.8) 1030 (64.3) 394 (60.7)
III-IV 2588 (36.6) 791 (45.6) 529 (34.3) 494 (31.8) 539 (33.7) 235 (36.3)
Missing 173 (2.4) 40 (2.3) 43 (2.8) 39 (2.4) 32 (2.0) 19 (2.9)
Cancer type, n (%)
Gastric cancer 3562 (50.3) 1004 (57.9) 788 (51.1) 737 (47.4) 715 (44.7) 318 (49.1)
Esophageal cancer 3518 (49.7) 729 (42.1) 754 (48.9) 819 (52.6) 886 (55.3) 330 (50.9)
Cancer stage, n (%)
Stage 0 191 (2.70) 24 (1.38) 24 (1.56) 29 (1.86) 52 (3.25) 62 (9.57)
Stage I 905 (12.8) 131 (7.56) 157 (10.2) 226 (14.5) 260 (16.2) 131 (20.2)
Stage II 924 (13.1) 155 (8.94) 200 (13.0) 252 (16.2) 236 (14.7) 81 (12.5)
Stage III 2824 (39.9) 688 (39.7) 601 (39.0) 615 (39.5) 671 (41.9) 249 (38.4)
Stage IV 2188 (30.9) 726 (41.9) 557 (36.1) 423 (27.2) 369 (23.1) 113 (17.4)
Missing 48 (0.7) 9 (0.5) 3 (0.2) 11 (0.7) 13 (0.8) 12 (1.9)
Admission type, n (%)
GP referral 5406 (76.4) 1071 (61.8) 1128 (73.2) 1303 (83.7) 1367 (85.4) 537 (82.9)
Emergency intake 1517 (21.4) 627 (36.2) 367 (23.8) 225 (14.5) 201 (12.6) 97 (15.0)
Missing 157 (2.2) 35 (2.0) 47 (3.0) 28 (1.8) 33 (2.0) 14 (2.1)
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to the reference group (‘9–17 days’) (Table 2); the multi-
variable adjusted HRs for all mental disorders were 1.07
(95% CI 0.91–1.25) for a waiting time of ‘1–8 days’, 0.86
(95% CI 0.73–1.01) for ‘18–29 days’, and 0.79 (95% CI
0.67–0.93) for ‘30–60 days’. A clear trend of decreasing
HRs with increasing waiting time was also noted (p for
trend < 0.0001). Similar patterns of HRs were noted for
mental disorders identified through hospital diagnosis or
through drug prescription alone. The results for depres-
sion and anxiety did not differ largely from all mental dis-
orders, although patients with the shortest waiting time
appeared to have higher risk of anxiety, but not depres-
sion, compared to the reference group (Table 2).
Time since treatment decision (follow-up period), psych-
ical status, cancer type, cancer stage, age group, education
level, marital status, whether or not having MDC meeting,
treatment plan or hospital volume did not modify these re-
sults further (Additional file 1: Table S1). The cumulative
incidence curves (Fig. 1) illustrate the occurrence of mental
disorders during follow-up by different groups of waiting
times (since the curves didn’t adjust for any covariates, they
actually reflect a hypothetical scenario that all patients
would survive during follow-up) and show that patients
with longer waiting times had lower cumulative incidence
rates of mental disorders after treatment decision.
Patients with previous mental disorders
Among 2179 patients with previous history of mental
disorders, 68.8% received psychological care after the de-
cision date of cancer treatment. Prolonged waiting time
for cancer treatment was associated with an increased
rate of hospital visits for mental disorders during the
first year after treatment (Table 3), illustrating a 37.5%
higher rate of psychiatric hospital care per increasing
waiting time (95% CI 15.6–63.5%, p for trend = 0.0002).
This risk elevation was more pronounced for patients
with only a history of psychiatric medication use but no
hospital visit for mental disorders before treatment (n =
1,361), for whom the rate of hospital visits increased by
49.0% per increasing waiting time group (95% CI 18.4%–
87.4%) during the first year after treatment. The pattern
was less clear beyond one year after treatment decision
or for psychiatric medication use (Table 3).
Sensitivity analysis
Analyses restricted to patients that received surgical treat-
ment alone yielded similar results as the primary ana-
lyses, with the exception that among patients with a
history of psychiatric disorders (n = 473), the elevated
rate of hospital visit for mental disorders by longer wait-
ing times appeared also beyond one year after treatment
Table 1 Characteristics of patients with a newly diagnosed esophageal or gastric cancer, by different waiting time groups
(Continued)
Treatment decided through multidisciplinary conference, n (%)
Yes 4080 (57.6) 668 (38.6) 929 (60.3) 990 (63.6) 1074 (67.1) 419 (64.7)
No 2953 (41.7) 1053 (60.8) 599 (38.9) 556 (35.7) 521 (32.5) 224 (34.6)
Missing 47 (0.7) 12 (0.6) 14 (0.8) 10 (0.7) 6 (0.4) 5 (0.7)
Planned treatment type, n (%)
Curative 3038 (42.9) 484 (27.9) 607 (39.4) 783 (50.3) 824 (51.5) 340 (52.5)
Palliative 2631 (37.2) 714 (41.2) 663 (43.0) 547 (35.2) 548 (34.2) 159 (24.5)
Supportive 1400 (19.8) 531 (30.6) 271 (17.6) 226 (14.5) 227 (14.2) 145 (22.4)
Missing 11 (0.1) 4 (0.3) 1 (0.0) 0 (0.0) 2 (0.1) 4 (0.6)
SD standard deviation, ASA American Society of Anesthesiologists
Table 2 Hazard ratios (HRs) and 95% confidence intervals (CIs)* for mental disorders among patients without mental disorder history
(n = 4,120), by different waiting time groups
Outcomes Number of cases 1–8 days 9–17 days 18–29 days 30–60 days
All mental disorders 1268 1.07 (0.91–1.25) 1.00 (reference) 0.86 (0.73–1.01) 0.79 (0.67–0.93)
Mental disorders identified by in-/out-patient diagnosis 129 0.79 (0.47–1.34) 1.00 (reference) 0.85 (0.54–1.33) 0.56 (0.34–0.93)
Mental disorders identified through drug prescription 1227 1.09 (0.93–1.29) 1.00 (reference) 0.88 (0.75–1.04) 0.82 (0.69–0.97)
Depression (ICD10:F32,F33 or/and ATC N06A) 317 0.96 (0.69–1.34) 1.00 (reference) 0.91 (0.67–1.23) 0.66 (0.48–0.92)
Anxiety (ICD10:F40,F41 or/and ATC N05B) 799 1.21 (0.99–1.48) 1.00 (reference) 0.87 (0.71–1.06) 0.84 (0.68–1.03)
*Adjusted for age, sex, marital status (single, married, divorce, widow/widower), education level (<9 years, 9–12 years, >12 years), physical status (The American
Society of Anesthesiologists (ASA) classification <2, 2 and above), cancer type (esophageal/gastric cancer), stage (0, I, II, III, IV stage), and planned treatment type
(curative, palliative, or supportive treatment), multidisciplinary meeting (yes/no), admission pathway (general physician referral / emergency intake), hospital
volume (low, median, high)
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(Additional file 2: Table S2). Alternative underlying time
scales barely changed the results (data not shown).
Discussion
The impact of waiting time for treatment has mostly
been studied in terms of cancer survival among patients
with esophageal or gastric cancer [8, 16]. To the best of
our knowledge, this is the first large nationwide cohort
study describing the association between waiting time
for cancer treatment and mental health in patients with
esophageal or gastric cancer. Our study sheds further
light on the complexity of waiting time management, by
highlighting a need to take into account different do-
mains of patient well-being in addition to the overall
survival. The complexity is further reflected by the
potential differential impact of waiting time for treatment
for different patients, depending on past psychiatric vul-
nerabilities. Specifically, while patients without any previ-
ous mental disorders may benefit from longer waiting
times, in terms of future mental health, patients with
previous mental disorders seem to benefit from a quick
treatment decision.
Long waiting times for diagnosis and treatment are
always of concern for the patients and the healthcare
providers [5]. In Sweden, factors that could affect the
waiting time of cancer treatment decision include the
speed of the completion of staging information (mainly
related to waiting time for radiological examinations),
patients’ wishes, as well as availability of MDC meeting
(which normally hold once per week, meaning up to six
Fig. 1 Cumulative incidence rates of mental disorders among patients without preexisting mental disorders
Table 3 Comparison of the rate of psychiatric care among patients with preexisting mental disorders (n = 2,312), by different
waiting time groups
Waiting
time
group
Hazard Ratios (HRs) and 95% Confidence Intervals (CIs)a
All psychiatric cares Hopsital visits Medication prescriptions
≤1 year >1 year ≤1 year >1 year ≤1 year >1 year
1–8 days 0.90 (0.74–1.10) 0.68 (0.44–1.07) 0.80 (0.49–1.31) 0.36 (0.14–0.91) 0.90 (0.74–1.10) 0.72 (0.46–1.13)
9–17 days 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
18–29 days 1.04 (0.86–1.26) 0.84 (0.51–1.24) 1.49 (0.98–2.25) 0.80 (0.38–1.72) 1.01 (0.83–1.23) 0.79 (0.51–1.22)
30–60 days 1.09 (0.91–1.32) 0.70 (0.47–1.02) 2.01 (1.24–3.24) 0.51 (0.24–1.07) 1.03 (0.85–1.24) 0.71 (0.48–1.04)
aEstimated by extended Cox model, adjusting for age, sex, marital status (single, married, divorce, widow/widower), education level (<9 years, 9–12 years, >12 years),
physical status (The American Society of Anesthesiologists (ASA) classification <2, 2 and above), cancer type (esophageal/gastric cancer), stage (0, I, II, III, IV stage), and
planned treatment type (curative, palliative, or supportive treatment), multidisciplinary meeting (yes/no), admission pathway (general physician referral / emergency
intake), hospital volume (low, median, high)
Song et al. BMC Cancer  (2017) 17:2 Page 6 of 9
days waiting time for some patients). According to our
NREV database, 70% of the patients with esophageal or
gastric cancer received treatment decision within 30 days
after cancer diagnosis. The median waiting time for oper-
ation was however more than two months (67 days), and
half of the patients received neoadjuvant therapy before
the operation. Reduction in the medical delays before
therapeutic intervention has proven to be of paramount
importance for critical and urgent conditions such as
stroke [17], myocardial infarction [18]. However, the im-
portance of medical delays for chronic diseases including
cancer is inconclusive. Most studies found null impact of
waiting time on cancer specific survival, including gastro-
esophageal [7, 8, 16], colorectal [19], lung [20], and pan-
creatic [6] cancers. Other studies claimed however that a
detrimental effect on the prognosis could be introduced if
certain waiting time threshold was exceeded. For example,
prolonged interval between diagnostic imaging and resec-
tion over 32 days for pancreatic cancer was associated
with significantly increased risk of unexpected tumor
progress as determined at laparotomy [21]. A recent
population-based study [22] emphasized a significantly
lower overall survival among patients with non-metastatic
invasive breast cancer after 30 days waiting time for
surgery (approximately 10% decreasing survival for every
30-day increment in waiting). Similarly, shorter overall
survival has been suggested for 60 and more days of
waiting time for head and neck cancers [23, 24], and for
12 and more days of waiting time for uterine cancers [25].
The psychological consequences of lengthy waiting time
for treatment among cancer patients remain largely un-
known. Our finding of the inverse assocation between
waiting time and new onset mental disorders corroborates
is unexpected, but corroborates the findings of a descrip-
tive study including 21 breast cancer patients [26], which
hypothesized that a proper interval between cancer diag-
nosis and start of treatment might be necessary and bene-
ficial in terms of facilitating psychological adaptation [27].
A retrospective Dutch study including 202 breast cancer
patients also implied that waiting time for diagnosis, but
not waiting time for surgery, could affect the emotional
well-being of cancer patients [28]. Considering that the
pressure of providing speedy treatment might lead to re-
duced care quality [29, 30], short waiting time scheme
should be designed and utilized with full caution.
Nevertheless, for patients with a history of mental dis-
orders, the necessity of speedy cancer treatment seems
to be justified. Clinical studies [31–33] indicated a similar
cancer incidence but excess cancer mortality among pa-
tients with psychiatric diagnoses, compared to individuals
without such comorbidity. Delayed diagnosis, and there-
fore a presentation at an advanced tumor stage at cancer
diagnosis might be one possible explanation underlying
such excess mortality [34]. However, UK researchers [35]
observed a worse survival outcome for cancer patients
with a history of mental illness, although these patients
did indeed not have more advanced cancers at diagnosis,
suggesting that the differential survival might instead be
driven by factors during the process of cancer care after
diagnosis. In the present study, we demonstrated that pa-
tients with history of psychiatric disorders with longer
waiting times for cancer treatment had increased needs of
hospital care for mental health during the first year after
treatment. Psychiatric symptoms might affect patients’
physical health, responsiveness to cancer treatment, and
compliance to treatment regime (e.g. tolerance to inten-
sive regimes) [33, 36], leading to altered overall survival in
the long run. Improved prognosis might therefore be ex-
pected as a consequence of investment in timely treat-
ment for such patients.
The major strength of our study is the large-scale
population-based cohort design, with all information re-
garding cancer diagnosis, treatment, and mental disorders
collected prospectively and independently. The linked data
from death and emigration registers ensured the com-
pleteness of follow-up information. The availability of de-
tailed questionnaire data from the quality register enabled
considerations of a wide range of patient and tumor char-
acteristics during the analysis.
Lack of data on the exact starting date of cancer treat-
ment is a limitation. But the similar results of the sensi-
tivity analysis by restricting to patients with surgical
treatment alone relieved this concern. Further, the appli-
cation of drug register for case identification, on one
hand, increased the sensitivity by capturing undiagnosed
patients who experienced difficulties in emotional re-
sponses [37], while reduced the possibility of underestima-
tion caused by the prioritized cancer management―this
might be especially true for patients in the shortest waiting
group (i.e., more advanced diseases), being indicated by in-
consistent HRs observed for diagnosed mental disorders
and disorders identified by medication. However, on the
other hand, the misclassification induced by this broad def-
inition might exist, considering that antidepressant drug
was not exclusively used for mental problems among can-
cer patients.
The potential influence of uneven mortality rates between
patients with different waiting times (i.e., competing risks)
on the present findings needs to be considered. However, in-
formative censoring should have been alleviated sufficiently
after adjusting for all prognostic indicators (i.e. cancer stage,
therapy type, admission pattern, etc.) in the regression
models. Also, similar results from subgroups analysis further
relieved such concern. Moreover, although we cannot rule
out possible residual confounding due to shared risk factors
between cancer and mental disorders, the divergent result
patterns between patients with and without mental disease
history argues clearly such possibility.
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Conclusions
In conclusion, our study suggests the treatment delays
after a diagnosis of esophageal or gastric cancer might
be detrimental for the mental health of patients with
preexisting mental disorder, at least during the first year
after treatment. For patients without a mental disorder
history, however, longer waiting times seem to be linked
with a lower risk of new onset mental disorders after
treatment.
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